Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of SOF10 plus atezolizumab in advanced solid tumors
jRCT2031200407Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ro7496353 in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started May 2021; status: active, not recruiting.
02
Drugs
ro7496353
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200407.